News & Updates

Taking diltiazem and direct oral anticoagulants (DOACs) together appears to contribute to increased bleeding risk in patients with atrial fibrillation (AF), regardless of the presence of chronic kidney disease, as shown in a study.

Exposure to single or multiple drugs can have extensive disruptive effects on the human gut microbiome, a new study has found.

Second-line treatment with the CAR* T-cell therapy axicabtagene ciloleucel (axi-cel) led to significantly longer event-free survival (EFS) in patients aged ≥65 years with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) compared with standard of care (SoC), according to a preplanned subgroup analysis of the ZUMA-7** trial presented at EHA 2022.

Discontinuation of proton pump inhibitor (PPI) use remains prevalent, even within a group of mostly academic gastroenterology (GI) practitioners, despite evidence suggesting the safety of long-term PPI use without routine monitoring, a study has shown.

In a study evaluating azole use in patients with atrial fibrillation (AF) on non-vitamin K antagonist oral anticoagulants (NOACs), systemic exposure to the antifungal agent fluconazole was associated with an elevated risk of bleeding, particularly among those on apixaban. Conversely, no association was seen between NOACs and topical azoles*.